SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease

Globally, diabetes mellitus is a leading cause of kidney disease, with a critical percent of patients approaching end-stage kidney disease. In the current era, sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as phenomenal agents in halting the progression of kidney disease. Positive...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanduri, Swetha R., Kovvuru, Karthik, Hansrivijit, Panupong, Thongprayoon, Charat, Vallabhajosyula, Saraschandra, Pivovarova, Aleksandra I., Chewcharat, Api, Garla, Vishnu, Medaura, Juan, Cheungpasitporn, Wisit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564486/
https://www.ncbi.nlm.nih.gov/pubmed/32846935
http://dx.doi.org/10.3390/jcm9092723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564486/
https://www.ncbi.nlm.nih.gov/pubmed/32846935
http://dx.doi.org/10.3390/jcm9092723

Ejemplares similares